$0 is the total value of RiverVest Venture Management LLC's 0 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $40,363,000 | +8.0% | 1,921,118 | 0.0% | 46.86% | -14.7% | |
| ALLK | Allakos, Inc. | $29,914,000 | +95.5% | 4,887,932 | 0.0% | 34.73% | +54.5% | |
| RPHM | Reneo Pharmaceuticals, Inc. | $8,071,000 | +26.4% | 2,409,220 | 0.0% | 9.37% | -0.1% | |
| Xilio Therapeutics, Inc. | $4,195,000 | -0.3% | 1,441,444 | 0.0% | 4.87% | -21.3% | ||
| SPRB | Spruce Bioscience, Inc. | $2,943,000 | -21.3% | 2,148,281 | 0.0% | 3.42% | -37.8% | |
| VAPO | Buy | Vapotherm, Inc. | $648,000 | -37.1% | 412,558 | +1.3% | 0.75% | -50.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Allakos, Inc. | 12 | Q3 2023 | 88.4% |
| Spruce Bioscience, Inc. | 12 | Q3 2023 | 16.4% |
| Vapotherm, Inc. | 12 | Q3 2023 | 6.0% |
| Mirum Pharmaceuticals, Inc. | 11 | Q2 2023 | 54.9% |
| Reneo Pharmaceuticals, Inc. Fund 4 | 10 | Q3 2023 | 47.7% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 16.5% |
| Otonomy, Inc. | 1 | Q4 2020 | 0.4% |
View RiverVest Venture Management LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-10-30 |
| 13F-HR | 2023-08-07 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-02 |
| 13F-HR | 2022-02-07 |
| 13F-HR | 2021-11-12 |
View RiverVest Venture Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.